Cipla gets USFDA nod for rare genetic condition treatment drug

Cipla's Icatibant injectable pre-filled syringe in the strength of 30mg/3mL is generic version of Shire's Firazyr, the company said in a regulatory filing.

Cipla share price rises on USFDA nod; surges 45% in 9 months

Cipla’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire’s Firazyr.

Coronavirus treatment | Cipla ramps up remdesivir capacity to meet surge in demand

Cipla also launched a dedicated 24x7 helpline and email channel to support patient access to these critical drugs exclusively during this pandemic outbreak.

Cipla launches generic version of remdesivir in India

Cipremi has been approved by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need.

Cipla, Boehringer Ingelheim to co-market 3 oral anti-diabetic drugs

The three drugs are Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin).

Cipla shares gain 2% on partnership with a German firm for anti-diabetic drugs

The stock has rallied 72 percent in last three months as pharma sector has been in focus during COVID-19 crisis

CSIR will now focus on clinical trial of combinations of drugs for COVID-19 treatment

Earlier, trials were limited to a few people but now we need a larger trial on around 600-700 people, said Shekhar Mande, Director General of CSIR.

Cipla to price generic version of COVID-19 drug remdesivir at less than Rs 5,000 per vial

Remdesivir is the only United States Food and Drug Administration (USFDA)-approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalised with suspected or laboratory confirmed COVID-19 infection.

Remdesiver, Favipiravir antiviral drugs 'no game changers' in COVID fight, say medical experts

Dr Avi Kumar, Consultant, Pulmonologist, Fortis Escort Heart Institute, said drugs such as Favipiravir and Remdisiver "cannot be called game changers" as they are used as a supportive treatment.

Big Story | Cipla, Hetero get regulator nod for Remdesivir: What this means for COVID-19 patients

Remdesivir has emerged as one of the most promising drug candidates in the treatment of COVID-19

Cipla shares end almost 3% higher on regulator nod to manufacture remdesivir

India's Drug Regulator gave permission to Hetero and Cipla to manufacture and market antiviral drug remdesivir for "restricted emergency use" on hospitalised COVID-19 patients, official sources said.

Cipla share price rises as it expands partnership with Roche Pharma

The two companies have entered into an agreement to provide better access to innovative medicines for patients in India.

Cipla to acquire 21.85% stake in GoApptiv

In the first stage, subscription of 15,392 compulsorily convertible preference shares and purchase of 6,927 equity shares is expected to be closed within 30 days from the execution date, subject to certain conditions precedent.

Buy Cipla target of Rs 738: Anand Rathi

Anand Rathi is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 738 in its research report dated May 28, 2020.

Cipla gets final nod from USFDA for migraine treatment nasal spray

"It has received final approval for its Abbreviated New Drug Application (ANDA) for Dihydroergotamine Mesylate nasal spray 4mg/mL from the United States Food and Drug Administration (USFDA) with a competitive generic therapy (CGT) designation," the company said in a filing to BSE.

Cipla Consolidated March 2020 Net Sales at Rs 4,376.19 crore, down 0.63% Y-o-Y

COVID-19 treatment | Cipla eyes multi-drug portfolio for novel coronavirus cure: Report

Cipla is reportedly fine tuning its pact with United States-based Gilead Sciences Inc. on patented intravenous drug remdesivir, a potential treatment for the respiratory infection.

Buy Cipla; target of Rs 655: HDFC Securities

HDFC Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 655 in its research report dated May 16, 2020.

Buy Cipla; target of Rs 670: ICICI Direct

ICICI Direct is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 670 in its research report dated May 18, 2020.

Cipla Consolidated March 2020 Net Sales at Rs 4,376.19 crore, down 0.63% Y-o-Y

Cipla: Respiratory pipeline adds oxygen, accumulate

Cipla submits application with USFDA for generic version of asthma drug

The company has submitted an abbreviated new drug application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the US Food and Drug Administration (USFDA), Cipla said in a regulatory filing.

Cipla share price gains 2% on Q4 numbers; files application for asthma drug with USFDA

The company announced the submission of an ANDA for Fluticasone propionate and Salmeterol inhalation powder with the US drug regulator.

Buy Cipla target of Rs 650: Sharekhan

Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 650 in its research report dated May 15, 2020.

Cipla reports Q4 profit at Rs 246 crore, FY20 net grows 1% to Rs 1,547 crore

The stock in the past year gained only 2.6 percent and rose 19.2 percent year-to-date.